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Abstract
It has been proposed that the structural and numerical
chromosome abnormalities recorded in breast cancer
could be the result of telomere dysfunction and that
telomerase is activated de novo to provide a survival
mechanism curtailing further chromosomal aberrations.
However, recent in vivo and in vitro data show that the
ectopic expression of telomerase promotes tumori-
genesis via a telomere length- independent mechanism.
In this study, the relation between telomerase expres-
sion and the extent of chromosomal aberrations was
investigated in 62 primary breast carcinomas. Telomer-
ase activity was measured using a polymerase chain
reaction–based telomeric repeat amplification protocol
assay and 92% of the tumors were found to express
telomerase with a relative activity ranging from 0 to
3839.6. Genetic alterations were determined by
G-banding and comparative genomic hybridization
analysis and 97% of the tumors exhibited chromoso-
mal aberrations ranging from 0 to 44 (average: 10.98).
In the overall series, the relationship between telo-
merase activity levels and genetic changes could be
best described by a quadratic model, whereas in
tumors with below-average genetic alteration num-
bers, a significant positive association was recorded
between the two variables (coefficient=0.374, P=
.017). The relationship between telomerase activity
levels and the extent of genetic alteration may reflect
the complex effect of telomerase activation upon
tumor progression in breast carcinomas.
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Introduction
Telomerase is a specialized ribonucleoprotein polymerase
directly involved in telomere maintenance by adding telo-
meric repeats onto chromosome ends [1,2]. Normally,
telomerase activity is detectable in germ line cells but not in
most differentiated somatic tissues. However, it is reactivated
in immortal cell lines and cancer cells [3,4 ]. The de novo
activation of telomerase in cancer possibly provides a
survival mechanism curtailing further chromosomal alter-
ations because it has been shown that telomere dysfunction
may lead to chromosomal aberrations in rapidly proliferating
cells [5]. Studies using a telomerase knockout mouse have
indicated that telomere deregulation leads to the develop-
ment of epithelial tumors with cytogenetic profiles similar to
those of human carcinomas [5,6 ]. However, its de novo
expression may also contribute to tumorigenesis. Constitu-
tive telomerase expression promotes mammary carcinomas
in aging mice in a tissue-specific manner [7 ]. Furthermore, in
cells with activated ras, the catalytic activity of telomerase
can contribute to tumorigenesis via a telomere length-
independent mechanism [8].
Clonal chromosomal changes have been documented in
over 500 breast carcinomas and the aberration pattern is
clearly nonrandom, with the most malignant tumors gen-
erally showing the most abnormal karyotype [9,10]. In
breast cancer as in most cancers, disease progression is
accompanied— and indeed probably driven— by a step-
wise accumulation of genomic abnormalities by the tumor
cells [11].
In order to test whether and how telomerase activation is
related to the extent and type of chromosomal aberrations in
breast cancer, we correlated telomerase activity levels in 62
primary breast carcinomas with genomic abnormalities
detected by G-banding and/or comparative genomic hybrid-
ization (CGH). G-banding is a screening method for both
balanced and unbalanced karyotypic changes, whereas
CGH helps detect gains and losses of genomic material
above a certain size irrespective of the mitotic activity of
tumor cells.
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Materials and Methods
Tumor Specimens
Sixty- two primary breast carcinomas were collected
from patients undergoing surgery at the Odense University
Hospital, Denmark, between 1992 and 1994. Parts of the
tumor samples for cytogenetic analysis were processed as
described below and those for telomerase activity deter-
mination and CGH analyses were stored at 808C until
further use. The mean age of the patients was 61 years
(range: 31–95 years).
Histopathology
Thehistopathologic classificationwasmade inaccordance
with WHO recommendations. The carcinomas were ductal
not otherwise specified (NOS), comedo, papillary, cribriform,
mucinous, lobular,mixedductal and lobular, ductal carcinoma
in situ (DCIS), and ductal carcinoma with extensive DCIS
component. The assessment of histological grade was based
on the aggregate score for three variables ( tubular formation,
mitotic index, and nuclear polymorphism) and was quantified
to allow a correlation study with the complexity of the genetic
changes. Each component was scored from 1 to 3, with their
sum corresponding to well -differentiated carcinoma grade I
(3–5 points), moderately differentiated carcinoma grade II (6
or 7points), andpoorly differentiated carcinomagrade III (8 or
9points).Thescores1and2foreachof the threecomponents,
as well as grades I and II, were grouped together for the
purposeof the statistical analysis.Estrogenandprogesterone
receptor expressions were determined on frozen tissue
sections using standard immunohistochemistry techniques
and were available for 43 of the tumors. A sample was
considered positive for receptors when more than 10% of the
cells showed positivity.
Telomerase Activity
Frozen breast cancer tissue samples were homogenized
in 200 l of lysis reagent precooled on ice. After 30 minutes
of incubation on ice, the lysates were spun down at 16,000g
for 20 minutes at 48C. The supernatants were carefully
removed and transferred to fresh tubes. The aliquots were
stored at 808C until further use. The protein concentration
was measured using the DC Protein Assay kit (BioRad,
Hercules, CA).
For the in vitro detection of telomerase activity, the
telomeric repeat amplification protocol (TRAP) assay
(TeloTAGGG Telomerase PCR ELISA plus detection kit;
Roche Molecular Biochemicals, Mannheim, Germany) was
used, according to Kim et al. [12]. Briefly, 10 g of tissue
extract was suspended in 30 l of reaction mixture
(containing biotinylated telomerase substrate, optimized
anchor primer, nucleotides, Taq polymerase, and a 216-bp
internal standard DNA). The resulting mixture was sub-
jected to polymerase chain reaction (PCR) for 30 cycles of
30 seconds at 948C, 30 seconds at 508C, and 90 seconds
at 728C. The telomerase activity was quantified by
measuring the absorbance of the PCR products at 450
nm (with a reference wavelength of approximately 690
nm). Each analysis included a telomerase-positive control
(high and low), heat - inactivated controls, and a negative
control (containing only lysis buffer ). The level of telomer-
ase activity in a given sample was determined by
comparing the signal from the sample to the signal
obtained using a known amount of control template.
Cytogenetic Analysis
The tumor cells were cultured in a short term and
analyzed cytogenetically after G-banding of the chromo-
somes as previously described [13]. Briefly, all samples
were mechanically and enzymatically disaggregated, and
the resulting cells were plated out in 25-cm2 Primaria flasks
or Vitrogen-coated slide flasks. The cultures were fed an
appropriate medium that facilitates epithelial growth and
harvested after 5 to 8 days. The cells were exposed to
demecolcine, dislodged by trypsinization, subjected to
hypotonic shock in 0.05 M KCl, and fixed in methanol:acetic
acid (3:1). G-banding was obtained with Wright stain. The
clonality criteria and the description of karyotypes followed
the recommendations of the ISCN (1995) [14]. The detailed
karyotypes have been reported [15,16].
CGH
CGH analysis DNA was isolated by phenol–chloroform
extraction according to Wigler et al. [17] with minor
modifications. CGH was performed according to Kallionemi
et al. [18] with the modifications described in detail by
Teixeira et al. [15 ]. Briefly, test ( tumor) and reference
(peripheral blood lymphocytes from a healthy female) DNA
were extracted using standard methods and labeled by nick
translation. The same amounts of labeled tumor and
reference DNA (800 ng each) were mixed with 20 g of
unlabeled CotI DNA (Life Technologies, Rockville, MD), and
ethanol precipitated, dried, and dissolved in hybridization
buffer (Vysis, Downers Grove, IL). Normal metaphases
were obtained by lymphocyte culture from healthy volunteers
or from commercially available slides (Vysis). After denatur-
ing the chromosomes and the DNA probe, hybridization was
allowed to occur for 2 to 3 days in a humidified chamber at
378C. After a series of washes, the slides were mounted in
an antifade solution with DAPI (Vectashield; Vector Labo-
ratories, Burlingame, CA). The threshold values 1.25 and
0.75 were used to score gain and loss of DNA sequences,
respectively. Analysis was performed with a CytoVision
system coupled to a Zeiss Axioplan fluorescence micro-
scope. The description of the CGH copy number changes
followed the guidelines of the ISCN (1995) [14] and has
been reported previously [15,16].
Evaluation of Genetic Complexity and Statistical Analysis
The karyotypic complexity ( i.e., the number of cytoge-
netic abnormalities detected by chromosome banding
analysis) was determined by counting the aberrations
described in the karyotype in each case according to the
following criteria: multiple copies of structural or numerical
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Table 1. Clinical Data and Telomerase Activity Values for 62 Patients.
Case number Histology* Gradey LNMz Age Telomerase activity Genetic changesx Er{ Pgr#
183 / 92 D ND No 59 549.1 6 ND** ND
194 / 92 D ND ND 77 395.2 1 ND ND
305 / 92 D 2,1,2 No 76 1636.2 1 ND ND
317 / 92 Com 3,3,2 No 48 843.8 15 ND ND
363 / 92 D 3,2,2 No 70 2303.2 4 P P
374 / 92 Lob ND Yes 71 2221.6 10 P P
386 / 92 D ND No 39 1750.6 13 ND ND
394 / 92 D 2,2,2 18 / 18 71 444.3 13 P P
395 / 92 Lob+DCIS ND ND 77 2237.2 5 P P
418 / 92 D+DCIS 3,1,2 ND 42 1597.8 5 P N
419 / 92 Com 3,3,3 Yes 50 2289.8 6 N N
423 / 92 Com 3,2,2 No 64 2128.6 9 N P
431 / 92 Com 3,3,3 No 50 2727.9 23 P P
435 / 92 Com 3,3,2 Yes 44 1413.0 7 N N
437 / 92 D 3,3,3 No 52 1574.8 2 N N
439 / 92 Com 3,1,3 9 / 11 31 1703.6 24 N N
455 / 92 D 3,1,2 No 84 0 1 P N
459 / 92 Lob ND Yes 65 0 1 P P
467 / 92 D 3,1,2 No 73 107.9 5 P P
487 / 92 D 3,2,2 Yes 71 6.2 2 P N
501 / 92 Crib 2,1,2 No 53 2634.2 3 ND ND
503 / 92 D 3,1,3 4 / 20 48 575.4 8 ND ND
509 / 92 D 3,2,3 No 61 1767.4 6 P P
512 / 92 D 3,3,3 19 / 19 44 841.9 25 N P
513 / 92 D 2,2,2, No 66 1919.3 8 P P
515 / 92 Papil ND 1 / 8 70 2944.7 21 P N
526 / 92 D 3,1,2 No 84 0 0 ND ND
529 / 92 D 1,1,2 Yes 74 321.4 3 P P
25 / 93 D 3,1,2 No 48 981.8 4 P P
26 / 93 D 3,2,2 No 67 198.3 6 P N
46 / 93 Crib 2,1,2 No 62 2574.7 2 P P
59 / 93 Com 2,2,3 Yes 77 1281.1 3 ND ND
80 / 93 Com 3,3,3 No 91 243.2 44 N N
92 / 93 D+DCIS 3,1,2 No 66 384.5 1 ND ND
97 / 93 Muc ND No 57 838.7 5 N N
100 / 93 Com 3,3,3 No 63 1201.2 18 ND ND
113 / 93 D 2,1,1 No 54 0 4 ND ND
119 / 93 Com 3,1,2 Yes 39 169.3 2 N N
136 / 93 D 3,1,2 No 57 2972.9 9 P N
138 / 93 D 3,2,3 No 51 0 4 P P
145 / 93 D 2,2,3 5 / 5 81 1192.7 40 N N
154 / 93 Lob ND ND 72 63.9 9 P P
156 / 93 Com 3,3,3 No 65 714.3 5 N N
167 / 93 Com 3,2,3 9 / 14 54 2641.7 22 N P
179 / 93 Med ND ND 55 225.1 2 N N
199 / 93 Com ND No 46 1545 33 N N
208 / 93 Com 3,3,3 No 60 16.2 25 N N
236 / 93 D+Lob 1,1,1 4 / 14 54 1397.7 3 N N
244 / 93 Muc ND No 95 627.2 21 ND ND
248 / 93 Com 3,3,2 No 59 582.5 32 N N
335 / 93 D 3,3,2 7 / 18 46 1281.6 23 P P
361 / 93 Com 3,2,2 4 / 24 63 7.8 16 P P
392 / 93 Com 3,1,2 No 70 1327.1 11 N N
467 / 93 D 3,1,2 No 72 3839.6 5 P N
495 / 93 DCIS ND No 52 289.8 2 ND ND
507 / 93 D 2,3,3 No 55 1397.7 16 N N
535 / 93 Lob ND No 40 643.4 6 ND ND
557 / 93 D 3,3,3 No 44 2008.6 16 ND ND
566 / 93 D 2,2,1 No 49 609 15 ND ND
574 / 93 D 2,2,1 No 62 210.7 5 P P
2 / 94 D 3,2,3 No 57 997.2 17 N N
7 / 94 Papil ND No 49 458.6 28 ND ND
*Com=comedo carcinoma; Crib=cribriform carcinoma; D=ductal carcinoma; DCIS=ductal carcinoma in situ; D+DCIS=ductal carcinoma with extensive in situ
component; Lob= lobular carcinoma; D+ lob=ductal and lobular carcinoma; Lob+DCIS= lobular carcinoma with extensive in situ component; Muc=mucinous
carcinoma; Med=medullary carcinoma; Papil =papillary carcinoma.
yHistological grade as subdivided in three components ( i.e., tubule formation, mitotic activity, ND nuclear pleomorphism).
zLymph node metastasis.
xTotal number of genetic changes detected by both techniques.
{Estrogen receptors.
#Progesterone receptors.
**ND=not determined (histological grading is done routinely only for ductal carcinoma NOS); N=negative; P=positive.
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abnormalities were counted only once; in derivative
chromosomes, each structural aberration was counted;
and each individual marker was counted once. The number
of genetic alterations detected by CGH was estimated by
adding the number of gains and losses as indicated by
Teixeira et al. [15 ]. Because the average number of
genetic changes detected by combined G-banding and
CGH was 11, samples were also divided into two groups
using 11 genetic alterations as the cutoff point. The
Spearman correlation coefficient and linear regression
analysis were used to assess any possible association
between the number of genomic aberrations (many and
few) and the relative level of telomerase activity. Fisher’s
exact test was calculated for each group to determine the
relationship between telomerase activity levels and cate-
gorical variables. The same tests were used to describe
the association of telomerase activity values to genomic
alterations detected by G-banding and CGH separately
(average of 6 and 8, respectively). Two- tailed P values
<.05 were considered statistically significant.
Results
Sixty- two primary breast carcinomas were analyzed for
telomerase activity and the majority of these samples
(92%) were found to be positive. Measurement of
telomerase activity revealed highly variable levels of
expression among the samples. The mean ( ±standard
Table 2. Spearman Correlations between Relative Telomerase Activity Levels and the Number of Chromosome Abnormalities (G -Banding ) and Copy Number
Changes (CGH).
Number of genetic
changes detected by G-Banding
Number of genetic
changes detected by CGH
Number of genetic changes
detected by G-Banding /CGH
Overall
population
Genetic
changes  6
Genetic
changes>6
Overall
population
Genetic
changes  8
Genetic
changes>8
Overall
population
Genetic
changes  11
Genetic
changes>11
Coefficient 0.077 0.093 0.108 0.211 0.380 0.236 0.247 0.374 0.109
P .553 .528 .713 .099 .014* .302 .053 .017* .630
The number of cytogenetic abnormalities in each case arrived at by counting the abnormalities described in the karyotype.
Multiple copies of structural or numerical abnormalities were counted only once; in derivative chromosomes, each structural change was counted. Each individual
marker was counted once.
The highest number of changes detected by G-banding or CGH was used for a combined score.
*Statistically significant finding.
Figure 1. Linear and quadratic curve estimation of the relationship between telomerase activity values and the number of genetic changes obtained by CGH
analysis in 62 primary tumors. The relation between telomerase activity values and the number of genetic aberrations is described by the quadratic model
Y=a+b1x+b2x
2, where Y represents telomerase activity and X is the number of genetic aberrations. The calculated values for b1 and b2 were 74.95 (P= .045 )
and 1.99 (P= .054 ), respectively.
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deviation) telomerase activity of the total population was
1126.7 ( ±950.8). Several clinical and histological charac-
teristics were used to determine the profile of the patients.
As shown in Table 1, information was available on 47 breast
carcinomas about the histological score, on 57 about lymph
node metastasis status, and on 57 about estrogen and
progesterone receptors. There was no obvious correlation
between telomerase activity and tumor size, lymph node
metastasis, mitotic index, tumor grade, and estrogen or
progesterone receptor status. A negative but not significant
association was seen between telomerase levels and age
(data not shown).
Figure 2. Spearman correlation between telomerase activity values and number of genetic changes determined by CGH analysis in tumor samples exhibiting less
than 14 (A ) or more than 19 (B ) genetic changes, respectively.
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As previously reported [15,16], the number of genetic
imbalances per case detected by both CGH and karyotypic
analysis in this series ranged from 0 to 45, with an average
of 10.98. The average number of genetic aberrations for the
same population was 6 and 8, detected only by G-banding
or CGH, respectively. Genetic aberrations detected by
either or both CGH and G-banding were seen in 60 of 62
of the carcinomas (97%) and in 56 of 57 telomerase-positive
tumors (98%). When the samples were divided in two
groups on the basis of the number of genetic aberrations,
using the average value (11) as the cutoff point ( tumors
with 11 or less aberrations, and tumors with more than 11
Figure 3. Spearman correlation between telomerase relative activity and the number of genetic changes in two histologic types: (A ) ductal NOS carcinomas and (B )
comedo carcinomas.
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aberrations), the mean value of telomerase activity did not
differ between the two groups. The Spearman correlation
coefficient revealed a statistically significant correlation
between telomerase activity and the number of genetic
aberrations detected by both CGH and G-banding (coef-
ficient=0.374, P=.017) within the former group of tumors
(Table 2).
The relation between telomerase activity values and the
number of genetic aberrations in the total population could be
best described by the quadratic model Y=a+b1x+b2x
2,
where Y represents telomerase activity and X is the number
of genetic aberrations (Figure 1). The calculated values for
b1 and b2 were 74.95 (P=.045) and 1.99 (P=.054),
respectively. According to this model, telomerase activity
increases as genetic changes accumulate and reaches its
maximum value when the number of genetic changes is
approximately 19. Thereafter, the relationship is reversed.
As shown in Figure 2, A and B, the linear positive
association existed between telomerase activity and the
number of genetic changes persisted up to approximately 14
genetic alterations (coefficient=0.369, P=.016). However,
tumors with over 19 genetic changes display a marginally
significant negative association between telomerase activity
and the number of genetic changes (coefficient=0.543,
P=.055).
The relationship between telomerase activity levels and
the number of genetic changes was also examined within the
histological subtypes with sufficient number of samples. As
shown in Figure 3, A and B, a positive association was
recorded in the ductal carcinoma group (coefficient=0.445,
P=.014). On the contrary, comedo carcinomas exhibited a
negative albeit not statistically significant relationship
between the two parameters (coefficient=0.029,
P=.911).
An effort was made to determine whether specific genetic
alterations were associated with telomerase activity. The
most frequent genetic aberrations in telomerase-positive
tumors were copy number gains of 1q, 8q, 16p, and 17q and
losses of 11q and 16q. However, none of the above
associations was statistically significant.
Discussion
Several lines of evidence suggest that the absence or low
levels of telomerase activity in rapidly proliferating cells lead
to gradual telomere attrition and that when telomeres shorten
below a minimal length, DNA damage pathways are
activated, resulting in loss of viability— a phenomenon
known as telomere- induced senescence [19]. Conversely,
telomerase activation permits survival and growth by
maintaining a minimal telomere length [3,20]. Evidence that
telomerase allows indefinite growth is provided by the fact
that the overwhelming majority of all human tumors even-
tually reactivate telomerase.
However, data suggesting an additional role for telo-
merase in maintaining telomere function, namely acceler-
ating or promoting proliferation, are now emerging [21].
Telomerase activity is upregulated in mouse carcino-
genesis in spite of the fact that mice have long telomeres
and, furthermore, constitutive expression of telomerase
promotes tissue-specific mammary carcinogenesis in
aging mice [7]. The most convincing evidence for an
alternative role for telomerase derives from the fact that the
ectopic expression of mutant hTERT, which retains its
catalytic activity but could not maintain telomere length,
contributes to tumorigenesis in collaboration with activated
H-Ras in ALT immortal cell lines [8].
To assess the involvement of telomerase in breast
cancer, telomerase activity levels were compared with the
total number of genetic alterations in samples from 62
breast carcinomas. The methods used to detect chromo-
somal aberrations were G-banding and CGH— a more
recently developed molecular cytogenetic method that
enables the detection of genetic imbalances in solid tumors
and their mapping on normal reference metaphase spreads
[18,22]. CGH investigations have been performed on
several tumor types, including breast cancer, and pre-
viously unknown gains, amplifications, and deletions have
been revealed [18,22,23].
Telomerase activity was detected in 92% of the primary
breast carcinomas— a result at par with the 71% to 95%
positive cases detected in other telomerase activity
studies [24–28]. The analysis by the two techniques—
G-banding and CGH— showed genetic aberrations in
97% of the total population. The average number of
genetic alterations was 11 per case, taking into consid-
eration the results of both techniques [15,16].
To assess any relationship between telomerase levels
and the extent of genetic changes, the samples were divided
into tumors with above-average and below-average genetic
changes. No difference was detected in the mean level of
telomerase activity. However, each group displayed a
different pattern of relationship between telomerase activity
and genetic alterations.
No linear correlation was found between telomerase
activity levels and genetic changes in the overall series;
instead, a quadratic model described better the relationship
between the two variables. According to this model,
telomerase activity increases as genetic changes accumu-
late. Telomerase activity reaches a maximum value when
the number of genetic changes approaches 19. Thereafter,
the relationship is reversed. A statistically significant positive
correlation emerged between telomerase activity and the
number of genetic aberrations in samples if they were fewer
than 14. In contrast, samples with more than 19 genetic
changes showed a negative but marginally significant
correlation with telomerase activity levels.
The contrasting relationships revealed by the data may
reflect a dual role for telomerase in breast cancer i.e., its
survival-conferring effect, superimposed upon its cell pro-
liferation-promoting function. It was recently reported that
human telomerase accelerates the growth of epithelial cells
through regulation of genes that mediate the RB–E2F
pathway [29]. It is possible that this latter effect may be
more prominent at earlier stages of tumor progression or
in certain tumor types, whereas in more advanced tumors
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( i.e., tumors with many genetic alterations or in different
tumor types), its survival role may persist.
An examination of the relationship between telomerase
activity and the number of genetic changes within histological
groups indicated that the pattern of relationship reflected the
number of genetic changes associated with each group.
Ductal carcinomas, which had an average of nine genetic
changes, displayed a positive association between the two
parameters. However, comedo carcinomas that are charac-
terized by extensive genetic alteration (mean value of 17)
exhibited a negative relationship between telomerase activity
and the number of genetic changes. However, relationships
observed within each histological group were not as strong
as the ones observed for the whole population, indicating
that the number of genetic alterations is the main determi-
nant of the type of relationship between the two parameters,
regardless of tumor histology.
Our data demonstrated a strong, direct relationship
between telomerase activity and genomic alterations in
ductal carcinoma and in the group with below-average
genetic changes. The finding may also be related to the
tumorigenic effect of telomerase. In the early stages of
tumorigenesis, telomerase activity probably reflects the
proliferation or differentiation function of the enzyme whose
activation may be caused by various oncogenic alterations
[30]. Tumor progression depicted by the observed accumu-
lation of genetic changes was found accompanied by an
increase of telomerase activity in breast cancer at least at the
initial stages. This may indicate that the de novo activation of
telomerase may promote tumorigenesis as has recently
been reported [7,8 ].
The negative association between telomerase activity and
the number of genomic alterations observed in comedo
carcinomas and/or tumors with above-average genetic
changes may reflect the fact that in this group, low
telomerase activity is associated with increased genetic
instability. Our data do not show a statistically significant
association to fully support this possibility. Thus, it is more
likely that these tumors may arise after telomere crisis and
the consequent massive chromosomal aberrations. Telo-
merase activation may be a subsequent event permitting
immortal growth because telomerase activity above a
threshold seems to be essential for continuous proliferation
[31]. This mode of tumorigenesis is illustrated by comedo
carcinomas (even though in situ tumors) that are charac-
terized by massive genomic aberrations. A larger number of
samples are required to delineate this issue.
Loveday et al. [32] found that specific copy number gains
and losses occurred more frequently in telomerase-positive
breast carcinomas compared to telomerase-negative
tumors. Statistical analysis of our series did not reveal any
impact of specific chromosomal regions on the fluctuations of
telomerase activity (data not shown).
Separate analysis of G-banding and CGH data did not
produce the same results in the comparisons with telomer-
ase status. More specifically, contrary to what was seen in
the analysis based on CGH data, there was no significant
correlation between telomerase activity and the number of
chromosomal abnormalities as recorded by G-banding in
the whole series or in any distinct group of samples.
The explanation for the differences between CGH and
G-banding with regard to telomerase activity is to be sought
in the fact that the two techniques are based on different
principles. CGH is a FISH-based screening technique that in
a quantitative manner detects average gains and losses of
genomic material in major tumor clones. Because CGH does
not require tumor metaphases and hence is independent of
the mitotic activity of clonal subpopulations, the technique is
free from selection biases and can detect ‘‘nonviable’’
clones. However, only imbalances present in a significant
proportion of the test sample are revealed by CGH, so any
intratumor heterogeneity manifesting itself as minor clones
will go unnoticed. Also the experimental approach to
measure telomerase activity depends on it being present
in a large proportion of the cells. There is no way to
correlate the genetic alterations of a specific clone
examined by G-banding with the telomerase status of that
particular clone.
Previous studies have assigned prognostic value to
telomerase expression in breast cancer, finding an associ-
ation between telomerase activity levels and higher histo-
logical tumor grades [24]. It has also been reported that the
incidence of lymph node metastasis in patients with
telomerase-negative tumors was lower than in patients
with telomerase-positive primary tumors [28]. In the
present study, no association was found between telomer-
ase activity and established clinicopathological indicators
such as tumor size, grade, lymph node metastases, and
estrogen/progesterone receptor expression, as was the
case of the study by Loveday et al. [32 ]. Therefore, the role
of telomerase activity as a prognostic marker in breast
cancer remains doubtful and must wait for a more detailed
evaluation.
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